Cara East
Research Subjects
Cara East has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro José Quiroz Alfaro
Universidad del Rosario, Bogota, Colombia
1 shared publication - Angela L. Brown
Cardiovascular Division, Department of Medicine, Washington University in St. Louis, St Louis, Missouri, USA
1 shared publication Barry T. Katzen
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
1 shared publication- Brian Lee Claggett
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School , 75 Francis Street, Boston, MA 02115
1 shared publication - Carlos Mena-Hurtado
Yale School of Medicine
1 shared publication - Cassandra D. Ford
Capstone College of Nursing, University of Alabama , Tuscaloosa, Alabama
1 shared publication
Latest Publications
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e037530
Adherence to Lipid‐Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta‐Analysis
Background: Persistently elevated low‐density lipoprotein cholesterol is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite the availability of lipid‐lowering therapy (LLT), most patients with ASCVD do not achieve guideline‐recommended low‐density lipoprotein cholesterol goals. Poor adherence to LLT is a key barrier to low‐density lipoprotein cholesterol lowering and may be associated with adverse cardiovascular outcomes. We conducted a systematic review and meta‐analysis to clarify the relationship between adherence to LLT and cardiovascular outcomes in patients with ASCVD. Methods: Systematic searches of PubMed, Embase, Scopus, and Cumulative Index to Nursing and Allied Health Literature were performed in March 2023 (updated September 2024). Observational studies in adults with clinical ASCVD reporting objective measures of adherence or persistence to LLT and cardiovascular outcomes, including death, cardiovascular death, and major adverse cardiovascular events, were included. Risk of bias was assessed using the Clinical Advances Through Research and Information Translation tool. Results: Of 12 466 unique records identified, 39 met the inclusion criteria. Most studies only reported adherence to statins (33/39), and most measured adherence using proportion of days covered (25/39). Using an adherence threshold of ≥80%, adherence to LLT was shown to statistically significantly reduce risk of death (hazard ratio [HR], 0.56 [95% CI, 0.34–0.92]; P =0.0268; I 2 95%), major adverse cardiovascular events (HR, 0.77 [95% CI, 0.68–0.86]; P =0.0007; I 2 83%), myocardial infarction (HR, 0.86 [95% CI, 0.79–0.95]; P =0.0147; I 2 0%), and non–statistically significant reductions in cardiovascular death (HR, 0.44 [95% CI, 0.12–1.60]; P =0.1528; I 2 92%) and ischemic stroke (HR, 0.83 [95% CI, 0.58–1.18]; P =0.1856; I 2 52%). Conclusions: In this systematic review and meta‐analysis, adherence to LLT was associated with reduced risk of cardiovascular events in patients with clinical ASCVD. Registration: URL: https://www.crd.york.ac.uk/prospero/ ; identifier: CRD42023427146.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e037530
Open AccessAdherence to Lipid‐Lowering Therapies and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta‐Analysis
Background: Persistently elevated low‐density lipoprotein cholesterol is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite the availability of lipid‐lowering therapy (LLT), most patients with ASCVD do not achieve guideline‐recommended low‐density lipoprotein cholesterol goals. Poor adherence to LLT is a key barrier to low‐density lipoprotein cholesterol lowering and may be associated with adverse cardiovascular outcomes. We conducted a systematic review and meta‐analysis to clarify the relationship between adherence to LLT and cardiovascular outcomes in patients with ASCVD. Methods: Systematic searches of PubMed, Embase, Scopus, and Cumulative Index to Nursing and Allied Health Literature were performed in March 2023 (updated September 2024). Observational studies in adults with clinical ASCVD reporting objective measures of adherence or persistence to LLT and cardiovascular outcomes, including death, cardiovascular death, and major adverse cardiovascular events, were included. Risk of bias was assessed using the Clinical Advances Through Research and Information Translation tool. Results: Of 12 466 unique records identified, 39 met the inclusion criteria. Most studies only reported adherence to statins (33/39), and most measured adherence using proportion of days covered (25/39). Using an adherence threshold of ≥80%, adherence to LLT was shown to statistically significantly reduce risk of death (hazard ratio [HR], 0.56 [95% CI, 0.34–0.92]; P =0.0268; I 2 95%), major adverse cardiovascular events (HR, 0.77 [95% CI, 0.68–0.86]; P =0.0007; I 2 83%), myocardial infarction (HR, 0.86 [95% CI, 0.79–0.95]; P =0.0147; I 2 0%), and non–statistically significant reductions in cardiovascular death (HR, 0.44 [95% CI, 0.12–1.60]; P =0.1528; I 2 92%) and ischemic stroke (HR, 0.83 [95% CI, 0.58–1.18]; P =0.1856; I 2 52%). Conclusions: In this systematic review and meta‐analysis, adherence to LLT was associated with reduced risk of cardiovascular events in patients with clinical ASCVD. Registration: URL: https://www.crd.york.ac.uk/prospero/ ; identifier: CRD42023427146.
- Open Access
- 5 February 2025
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (2) , 170
Sex differences after PCI are not explained by comorbidities
- 5 February 2025
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (2) , 170
Open AccessSex differences after PCI are not explained by comorbidities
- Top Cited PapersOpen Access
- 1 October 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (10) , e135-e148
Renal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. In fact, only 23% of individuals with high blood pressure in the United States achieve treatment goals. In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This approval followed the publication of multiple randomized clinical studies using rigorous trial designs, all incorporating renal angiogram as the sham control. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant. Individual patient responses vary, and further research is needed to identify those who may benefit most. The initial safety profile appears favorable, and multiple ongoing studies are assessing longer-term efficacy and safety. Multidisciplinary teams that include hypertension specialists and adequately trained proceduralists are crucial to ensure that referrals are made appropriately with full consideration of the potential risks and benefits. Incorporating patient preferences and engaging in shared decision-making conversations will help patients make the best decisions given their individual circumstances. Although further research is clearly needed, renal denervation presents a novel treatment strategy for patients with uncontrolled blood pressure.
- 1 October 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (10) , e135-e148
Top Cited PapersOpen AccessRenal Denervation for the Treatment of Hypertension: A Scientific Statement From the American Heart Association
Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Despite the widespread availability of both pharmacological and lifestyle therapeutic options, blood pressure control rates across the globe are worsening. In fact, only 23% of individuals with high blood pressure in the United States achieve treatment goals. In 2023, the US Food and Drug Administration approved renal denervation, a catheter-based procedure that ablates the renal sympathetic nerves, as an adjunctive treatment for patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This approval followed the publication of multiple randomized clinical studies using rigorous trial designs, all incorporating renal angiogram as the sham control. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant. Individual patient responses vary, and further research is needed to identify those who may benefit most. The initial safety profile appears favorable, and multiple ongoing studies are assessing longer-term efficacy and safety. Multidisciplinary teams that include hypertension specialists and adequately trained proceduralists are crucial to ensure that referrals are made appropriately with full consideration of the potential risks and benefits. Incorporating patient preferences and engaging in shared decision-making conversations will help patients make the best decisions given their individual circumstances. Although further research is clearly needed, renal denervation presents a novel treatment strategy for patients with uncontrolled blood pressure.
- Open Access
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e028942
Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI
Background: Studies demonstrated sex differences in outcomes following acute myocardial infarction, with women more likely to develop heart failure (HF). Sacubitril/valsartan has been shown to reduce cardiovascular death and HF hospitalizations in patients with HF with reduced ejection fraction. Methods and Results: A total of 5661 patients (1363 women [24%]) with acute myocardial infarction complicated by reduced left ventricular ejection fraction (≤40%), pulmonary congestion, or both and ≥1 of 8 risk‐augmenting factors were randomized to receive sacubitril/valsartan or ramipril. The primary outcome was cardiovascular death or incident HF. Baseline characteristics, clinical outcomes, and safety events were compared according to sex, a prespecified subgroup. Female participants were older and had more comorbidities. After multivariable adjustment, women and men were at similar risks for cardiovascular death or all‐cause death. Women were more likely to have first HF hospitalization (hazard ratio [HR], 1.34 [95% CI, 1.05–1.70]; P =0.02) and total HF hospitalizations (HR, 1.39 [95% CI, 1.05–1.84]; P =0.02). Sex did not significantly modify the treatment effect of sacubitril/valsartan compared with ramipril on the primary outcome ( P for interaction=0.11). Conclusions: In contemporary patients who presented with reduced left ventricular ejection fraction, pulmonary congestion, or both, following acute myocardial infarction, women had a higher incidence of HF during follow‐up. Sex did not modify the treatment effect of sacubitril/valsartan relative to ramipril. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02924727.
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e028942
Open AccessSex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI
Background: Studies demonstrated sex differences in outcomes following acute myocardial infarction, with women more likely to develop heart failure (HF). Sacubitril/valsartan has been shown to reduce cardiovascular death and HF hospitalizations in patients with HF with reduced ejection fraction. Methods and Results: A total of 5661 patients (1363 women [24%]) with acute myocardial infarction complicated by reduced left ventricular ejection fraction (≤40%), pulmonary congestion, or both and ≥1 of 8 risk‐augmenting factors were randomized to receive sacubitril/valsartan or ramipril. The primary outcome was cardiovascular death or incident HF. Baseline characteristics, clinical outcomes, and safety events were compared according to sex, a prespecified subgroup. Female participants were older and had more comorbidities. After multivariable adjustment, women and men were at similar risks for cardiovascular death or all‐cause death. Women were more likely to have first HF hospitalization (hazard ratio [HR], 1.34 [95% CI, 1.05–1.70]; P =0.02) and total HF hospitalizations (HR, 1.39 [95% CI, 1.05–1.84]; P =0.02). Sex did not significantly modify the treatment effect of sacubitril/valsartan compared with ramipril on the primary outcome ( P for interaction=0.11). Conclusions: In contemporary patients who presented with reduced left ventricular ejection fraction, pulmonary congestion, or both, following acute myocardial infarction, women had a higher incidence of HF during follow‐up. Sex did not modify the treatment effect of sacubitril/valsartan relative to ramipril. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02924727.
- Open Access
- 7 March 2023
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 18, e06
Renal Denervation: A Practical Guide for Health Professionals Managing Hypertension
Growing evidence demonstrates the suitability of renal denervation in a broad population of patients; however, questions remain over its suitability and practical implementation. Given the rapidity of emerging data, this has been a challenging field for potential adopters to navigate. The purpose of this article is twofold: to provide navigation through emerging clinical data and evolving guidance; and to provide physicians with practical, evidence-based advice for identifying eligible patients and providing appropriate management in the pre- and postintervention settings. Although many of these recommendations are based on existing published guidance documents, we reflect equally on our own experiences of using this technology.
- 7 March 2023
- Published by Radcliffe Medical Media Ltd in Interventional Cardiology: Reviews, Research, Resources
- Vol. 18, e06
Open AccessRenal Denervation: A Practical Guide for Health Professionals Managing Hypertension
Growing evidence demonstrates the suitability of renal denervation in a broad population of patients; however, questions remain over its suitability and practical implementation. Given the rapidity of emerging data, this has been a challenging field for potential adopters to navigate. The purpose of this article is twofold: to provide navigation through emerging clinical data and evolving guidance; and to provide physicians with practical, evidence-based advice for identifying eligible patients and providing appropriate management in the pre- and postintervention settings. Although many of these recommendations are based on existing published guidance documents, we reflect equally on our own experiences of using this technology.
- 24 August 2022
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (1) , 128-129
An occult iatrogenic pneumothorax as a cosmetic procedure complication
A pneumothorax is the abnormal gas accumulation within the pleural space. We present a case of a patient with an occult iatrogenic pneumothorax who presented with symptomatic anemia that substantially improved after a transfusion, diverting the clinical suspicion. As a result, she developed acute respiratory distress, initially considered secondary to a possible pulmonary embolism vs. fat embolism. After computed tomography confirmed the diagnosis, a chest tube was inserted. This case emphasizes the importance of suspecting pneumothorax secondary to cosmetic procedures and using computed tomography as the first diagnostic tool in complex cases since chest x-rays can miss pneumothorax.
- 24 August 2022
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (1) , 128-129
An occult iatrogenic pneumothorax as a cosmetic procedure complication
A pneumothorax is the abnormal gas accumulation within the pleural space. We present a case of a patient with an occult iatrogenic pneumothorax who presented with symptomatic anemia that substantially improved after a transfusion, diverting the clinical suspicion. As a result, she developed acute respiratory distress, initially considered secondary to a possible pulmonary embolism vs. fat embolism. After computed tomography confirmed the diagnosis, a chest tube was inserted. This case emphasizes the importance of suspecting pneumothorax secondary to cosmetic procedures and using computed tomography as the first diagnostic tool in complex cases since chest x-rays can miss pneumothorax.
- 1 October 2015
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 9 (10) , 769-779
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial
- 1 October 2015
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 9 (10) , 769-779
An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial